TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22160383
Drug: Bortezomib-based treatment
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-based treatment before and after autologous stem cell transplantation (arm B)
Study: 22160383
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment without bortezomib (arm A)
Study: 7594088
Drug: Nitroglycerin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin with oral hydralazine (75 mg four times a day, group II, 14 patients)
Study: 1988576
Drug: E 50
Normalized name: Fe 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E 50 mg/m2 and prednisolone (LEP)
Study: 1988576
Drug: E 100
Normalized name: lysine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: E 100 mg/m2 and prednisolone (HEP)
Study: 19930092
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored oral health educational programme
Study: 24372439
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral health educational programme
Study: 9417158
Drug: Intravenous A1PI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous A1PI (60 mg/kg) infused on days 0, 4, 7, and 14
Study: 7639298
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (0.2 mg/ml twice daily for five days)
Study: 15313300
Drug: Placebo (balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (balanced saline solution)
Study: 2231212
Drug: Maintenance indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance indomethacin therapy (0.2 mg/kg/day for 5 days)
Study: 2231212
Drug: Standard indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard indomethacin therapy (three doses) followed by placebo (equivalent volume for 5 days)
Study: 28762081
Drug: Previous standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous standard-of-care treatments
Study: 23856660
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide plus intravenous B-vitamins
Study: 22019968
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current therapy at 40 Hz
Study: 22019968
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current therapy at 100 Hz
Study: 22019968
Drug: Interferential current
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferential current therapy at 180 Hz
Study: 22019968
Drug: Sham interferential
Normalized name: thymol
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham interferential current therapy
Study: 8305323
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream (single application)
Study: 8305323
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream (3 days once-daily therapy)
Study: 8305323
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream (5 days once-daily therapy)
Study: 8305323
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream (7 days once-daily therapy)
Study: 3385111
Drug: Standard trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard trivalent influenza vaccine (15 micrograms of B/USSR/100/83) + placebo
Study: 3385111
Drug: Standard trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard trivalent vaccine (15 micrograms of B/USSR/100/83) + supplemental dose (45 micrograms of B/USSR)
Study: 3385111
Drug: Supplemental dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental dose (45 micrograms of B/USSR) + placebo
Study: 31045894
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg neostigmine/0.5 mg atropine (n = 11)
Study: 31045894
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg sugammadex (n = 11)
Study: 12880604
Drug: Liquid nutrition
Normalized name: Liquid Nutrition Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid nutrition supplement
Study: 9088996
Drug: L-asparaginase treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-asparaginase treatment (10,000 U/m2 every 3-4 days)
Study: 9088996
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli preparation Asparaginase medac (2500 U/m2)
Study: 9088996
Drug: Erwinia preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erwinia preparation Erwinase
Study: 2020921
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (600 mg)
Study: 18751626
Drug: Antenatal perineal
Normalized name: Bos taurus pineal gland preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal perineal massage (10 minutes daily from 34 weeks of gestation until delivery)
Study: 16916298
Drug: Homapak (fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homapak (fixed-dose CQ+S/P combination)
Study: 16916298
Drug: GMP made
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMP made drugs
Study: 10704627
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (E2) valerate, 2 mg/day
Study: 10704627
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 gel, 1 mg/day
Study: 24259265
Drug: Capsaicin 8%
Normalized name: CAPSAICIN 8% PATCH KIT,4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin 8% cutaneous patch
Study: 15181577
Drug: Quadrivalent human/bovine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent human/bovine reassortant rotavirus vaccine
Study: 11434846
Drug: Otikon Otic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otikon Otic Solution (naturopathic herbal extract)
Study: 8281886
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet and physical training (1 h twice weekly and daily bicycle ergometry for 30 min)
Study: 2815173
Drug: Systemic metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic metronidazole therapy
Study: 2815173
Drug: Mechanical local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical local therapy
Study: 31199291
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual plus Videoconferencing (TAU-VC)
Study: 28495863
Drug: Soluble urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble urokinase plasminogen activator receptor >11,633 pg/ml (third tertile)
Study: 28495863
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of soluble urokinase plasminogen activator receptor to a risk factor model
Study: 25400106
Drug: 0% L-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% L-arabinose in meal A (sucrose and starch from wheat flour)
Study: 25400106
Drug: 5% L-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% L-arabinose in meal A (sucrose and starch from wheat flour)
Study: 25400106
Drug: 10% L-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% L-arabinose in meal A (sucrose and starch from wheat flour)
Study: 25400106
Drug: 0% L-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0% L-arabinose in meal B (starch from wheat flour)
Study: 25400106
Drug: 20% L-arabinose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% L-arabinose in meal B (starch from wheat flour)
Study: 25400106
Drug: Liquid meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid meal with maltose and 0% L-arabinose
Study: 25400106
Drug: Liquid meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid meal with maltose and 20% L-arabinose
Study: 21199857
Drug: 1-dose varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose varicella vaccination
Study: 16458964
Drug: Fixed-combination latanoprost-timolol
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-combination latanoprost-timolol
Study: 14769716
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride pills (medication)
Study: 8406350
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU interferon-alpha 2b (in combination with GM-CSF)
Study: 2446054
Drug: Ketanserin (20‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20‐80 mg daily)
Study: 2446054
Drug: Alpha-methyldopa (500‐2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-methyldopa (500‐2000 mg daily)
Study: 31839432
Drug: TPF induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF induction chemotherapy in normal BMI and clinical stage IVA disease
Study: 24001888
Drug: Intravenous golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous golimumab 2 mg/kg + methotrexate (MTX)
Study: 25224125
Drug: neuro-music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: neuro-music therapy (counseling plus eight 50-minute sessions of individualized music therapy)
Study: 19191657
Drug: Boosted protease
Normalized name: protease
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boosted protease inhibitor therapy (control)
Study: 16846509
Drug: Extended care
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL LIQUID [EXTENDED CARE Foaming Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended care treatment groups
Study: 9229195
Drug: Acipimox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox (250 mg, twice daily)
Study: 8250301
Drug: Alfentanil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (both doses)
Study: 1994667
Drug: Pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (10 mg twice daily)
Study: 27389975
Drug: ABT-494 (3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 (3, 6, 12, or 18 mg twice daily)
Study: 27389975
Drug: ABT-494 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 (12 and 18 mg)
Study: 27389975
Drug: ABT-494 (6-18
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-494 (6-18 mg)
Study: 20582466
Drug: Pq1wC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pq1wC (paclitaxel 60 mg/m(2) days 1, 8, 15, carboplatin AUC 6 day 1 for every 3 weeks)
Study: 20582466
Drug: Pq3wC (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pq3wC (paclitaxel 175 mg/m(2) day 1, carboplatin AUC 6 d1, every 3 weeks)
Study: 18618000
Drug: AA versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA versus CC diplotype frequency
Study: 12061945
Drug: riluzole 100
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: riluzole 100 mg/day (50 mg b.i.d.)
Study: 11956263
Drug: Concurrent cisplatin‐RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cisplatin‐RT (CRT) - cisplatin 40 mg/m² weekly for up to 8 weeks with radical RT
Study: 11956263
Drug: Concurrent cisplatin‐RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent cisplatin‐RT (CRT)
Study: 7978475
Drug: TTSF-75 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTSF-75 patch (75 micrograms/h)
Study: 7978475
Drug: TTSF-50 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTSF-50 patch (50 micrograms/h)
Study: 7978475
Drug: TTSF-50 and
Normalized name: ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TTSF-50 and TTSF-75 patches
Study: 7978475
Drug: TTSF patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTSF patches
Study: 7978475
Drug: TTSF-75 patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTSF-75 patch
Study: 3173046
Drug: Naloxone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2 mg)
Study: 31812719
Drug: 5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 Gy × 5 fractions of precision radiation therapy
Study: 25497513
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering treatment (target SBP <140 mmHg within 1 hour)
Study: 25497513
Drug: Guideline‐recommended blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline‐recommended blood pressure lowering treatment (target SBP <180 mmHg)
Study: 21790298
Drug: Medikinet retard
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medikinet retard (lower daily dose, similar IR components in the morning)
Study: 11204897
Drug: Alcohol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.6 g/kg for males and 0.5 g/kg for females)
Study: 22502839
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without TEAS treatment (n=39)
Study: 17361105
Drug: HSP90 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HSP90 inhibitor 17-allylaminogeldanamycin
Study: 11899948
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg after a high-fat meal
Study: 11899948
Drug: Tibolone 2.5
Normalized name: tibolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone 2.5 mg after fasting
Study: 7341547
Drug: d,1-Carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,1-Carnitine (3 g/daily)
Study: 30308560
Drug: AAV2-REP1 gene
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-REP1 gene therapy (0.1-mL subretinal injection of 10 genome particles)
Study: 31465092
Drug: AAV2-REP1 gene
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-REP1 gene therapy
Study: 25154896
Drug: 6.4% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4% glucose (CHO) solution
Study: 17606839
Drug: Bendroflumethiazide 5
Normalized name: bendroflumethiazide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide 5 mg
Study: 17606839
Drug: Amiloride 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 40 mg
Study: 7784236
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy plus prednisone
Study: 21412168
Drug: Cisplatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (40 mg/m intravenous) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2
Study: 21412168
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m IV) weekly on day 2 + phenoxodiol (3 mg/kg) weekly on days 1 and 2
Study: 19638927
Drug: Conventional clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional clamp crushing method (CC group)
Study: 11916756
Drug: 7 mg
Normalized name: pectin 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 mg threonine x kg(‐1) x d(‐1)
Study: 11916756
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg threonine x kg(‐1) x d(‐1)
Study: 11916756
Drug: 46 mg
Normalized name: lufenuron 46 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 46 mg threonine x kg(‐1) x d(‐1)
Study: 9802665
Drug: Professional physical
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional physical therapy
Study: 33753
Drug: Alkaline artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkaline artificial tear preparation
Study: 33753
Drug: Current artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current artificial tear preparations available in North America
Study: 30445507
Drug: Learn to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learn to Quit (LTQ) app combined with nicotine replacement therapy and technical coaching
Study: 30445507
Drug: NCI QuitGuide
Normalized name: Belagenpumatucel-L (NCI H-520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCI QuitGuide (QG) app combined with nicotine replacement therapy and technical coaching
Study: 10096452
Drug: Chlorphenylamine (CP),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorphenylamine (CP), administered daily for 7 days
Study: 10096452
Drug: Flurbiprofen (FB),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (FB), administered daily for 7 days
Study: 7755942
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg naproxen twice a day
Study: 2129651
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg aminophylline i.v.
Study: 2129651
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg doxofylline i.v.
Study: 2129651
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg doxofylline i.v.
Study: 28126304
Drug: 5-fluorouracil/mitomycin-C/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/mitomycin-C/radiation therapy (Arm A)
Study: 28126304
Drug: 5-fluorouracil/cisplatin/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil/cisplatin/radiation therapy (Arm B)
Study: 17386123
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and weekly paclitaxel
Study: 16033307
Drug: Overall risk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall risk of repeat therapy due to any recurrent infection
Study: 11981007
Drug: Ibandronate 2
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2 mg IV monthly for 12 to 24 months
Study: 11981007
Drug: Ibandronate 2
Normalized name: ibandronate 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 2 mg IV monthly
Study: 7530984
Drug: Tumour-infiltrating lymphocyte
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour-infiltrating lymphocyte (TIL) infusion
Study: 27749225
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of NSAIDs
Study: 18257344
Drug: Slowly-releasing medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slowly-releasing medication (intramuscular injection, made from Chinese herbs, administered at specific acupuncture points)
Study: 18257344
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Rythmol, oral administration, 150 mg thrice daily)
Study: 17023280
Drug: 0.3% ropivacaine/fentanyl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% ropivacaine/fentanyl, 3 microg/mL
Study: 17023280
Drug: 0.25% bupivacaine/fentanyl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% bupivacaine/fentanyl, 3 microg/mL
Study: 14514745
Drug: Protocolized anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized anemia management with subcutaneous rHuEpo and intravenous iron
Study: 10810685
Drug: Patient-controlled continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled continuous infusion of lidocaine (2% solution, 2 cc/h continuous dose, 1 cc at 15-minute intervals for 72 hours)
Study: 1666917
Drug: Oral CBD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CBD (10 mg/kg/day = about 700 mg/day) for 6 weeks
Study: 7105820
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg chlormezanone at night
Study: 7105820
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg diazepam 3-times daily for 4 weeks
Study: 27584142
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (monitoring, G3)
Study: 26013912
Drug: Cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanol (CF) intake (450 mg CF) bi-daily for 14 days
Study: 26013912
Drug: Nutrient-matched, CF-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient-matched, CF-free control drink bi-daily for 14 days
Study: 9388311
Drug: Electro-acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture treatment
Study: 17224808
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus patient choice of acupuncture, chiropractic, or massage therapy (choice)
Study: 3207560
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg single dose) with indomethacin pretreatment (25 mg four times daily for 3 days)
Study: 3207560
Drug: Indomethacin treatment
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin treatment alone
Study: 2444797
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg single dose)
Study: 30827852
Drug: Low-energy extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporeal shockwave therapy (0.05-0.20mJ/mm2, frequency of 4Hz, 1000 to 2000 shocks, once per week for 4 weeks)
Study: 24004232
Drug: Butorphanol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol (0.4 mg/kg, SC)
Study: 24004232
Drug: Methadone (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (0.6 mg/kg, SC)
Study: 19397429
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.25% bupivacaine infiltration
Study: 1972861
Drug: xamoterol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: xamoterol, 200 mg twice a day
Study: 93486
Drug: Individual speech
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual speech therapy
Study: 31045830
Drug: Soshiho-tang (SSHT)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soshiho-tang (SSHT) administered 3 times a day for 4 weeks
Study: 31914034
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 3 times a day for 4 weeks